Genetic inactivation through CRISPR/CAS9 technology of the DNA mismatched repair gene MutL homologue 1 (MLH1) in TS/A cells, as well as in other non-mammary murine cancer models, led to increased immunogenicity due to accumulation of neoantigens [147]. This evidence concerns the gene MLH1 and cancer.